A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Jun 2014
At a glance
- Drugs Tozasertib (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 26 Jan 2010 Planned end date (Apr 2007) added as reported by ClinicalTrials.gov.
- 26 Jan 2010 Official Title amended as reported by ClinicalTrials.gov.
- 19 Nov 2007 Status change from in progress to discontinued.